DRD2-mediated preclinical efficacy of ONC206 in endometrial cancer
ONC206 is effective in preclinical models of an aggressive subtype of endometrial cancer due to DRD2 antagonism. Please find the full paper here.
In The News
-
AUG 28 2020
-
-
AUG 27 2020
FDA Approves Foundation Medicine’s FoundationOne®Liquid CDx
This pan-tumor liquid biopsy test will include testing for the H3 K27M mutation. Please find more information here.
-
-
JUL 08 2020
Bryce Istvan Discusses His Experience at Oncoceutics
Please find the full article here.
-
-
JUN 01 2020
ASCO 2020: Oncoceutics’ ONC201 Demonstrates Clinical Benefit
Please find the full article here.
-
Business Development
© Copyright 2020 Oncoceutics, Inc. All Rights Reserved.